Deborah Research is supporting development of a self-cooling sole for sneakers to address blister problems in EB patients.
“We are, for instance, supporting a grant, which develops a cooling soul, for sneakers for patients. Patients, some patients, and too many patients have problems with defeat with blisters on defeat and problems with wearing sneakers. So, we're we're supporting a group that develops a self cooling soul, which can be put into into, sneakers.”
→ Read the source episode
Our resolution criterion
disputableA self-cooling sole product for sneakers is developed and becomes available for EB patients.
More from Beyond Biotech
Stuart Medina predicts Bio Spain 2026 Talent Day will exceed the 125 job interviews arranged in the previous year
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
Laurent Levy predicts Nanobiotics will complete pancreatic, melanoma, and esophageal cancer trials before H1 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.